Long-lasting Psychotomimetic Consequences of Repeated Low-dose Amphetamine Exposure in Rhesus Monkeys
Overview
Authors
Affiliations
The dopamine hypothesis of schizophrenia posits that dopamine dysregulation plays a key role in the etiology of schizophrenia. In line with this hypothesis, repeated amphetamine (AMPH) exposure has been shown to alter dopamine systems and induce behaviors reminiscent of positive-like and negative-like symptoms in both human and nonhuman primates. The mechanisms by which AMPH produces disturbances in brain function and behavior are not fully understood. The present study has employed a novel AMPH regimen, 12 weeks of intermittent escalating low doses of AMPH, to produce a nonhuman primate model for the purpose of elucidating the behavioral and neural consequences of excessive dopamine exposure. Behavioral responses to acute AMPH challenge (0.4-0.46 mg/kg) were assessed prior to and following the chronic 12-week treatment regimen, and, at present monkeys have been followed out to 28 months post-treatment. After chronic treatment, enhanced behavioral responses to AMPH challenge were readily apparent at 5 days postwithdrawal, and, were still present at 28 months postwithdrawal. The enhanced behavioral responses to low-dose AMPH challenge that were observed in the present study resemble closely the behavioral profile that has been described for chronic high-dose AMPH treatment in monkeys; i.e., hallucinatory-like behaviors, static posturing, and fine-motor stereotypies were all exacerbated in response to AMPH injection. In some animals, acute challenges after chronic AMPH evoked aberrant behavioral responses that lasted for 4 days. AMPH-treated monkeys also exhibited a significant decrease in the incidence of motor stereotypies in the off-drug periods between challenges. The present results are the first to document persistent long-term behavioral effects of intermittent exposure to repeated low-dose AMPH treatment in nonhuman primates. These findings may lay the groundwork for the development of a primate mode of psychosis with possible positive-like and negative-like symptoms.
Reevaluating ADHD and its First-Line Treatment: Insights from DSM-5-TR and Modern Approaches.
Ophir Y Clin Neuropsychiatry. 2024; 21(5):436-443.
PMID: 39540077 PMC: 11555658. DOI: 10.36131/cnfioritieditore20240507.
Does stimulant drug-induced sensitization occur in primates?.
Leyton M J Psychiatry Neurosci. 2022; 47(2):E148-E152.
PMID: 35418507 PMC: 9259430. DOI: 10.1503/jpn.220055.
Modulation of dopamine tone induces frequency shifts in cortico-basal ganglia beta oscillations.
Iskhakova L, Rappel P, Deffains M, Fonar G, Marmor O, Paz R Nat Commun. 2021; 12(1):7026.
PMID: 34857767 PMC: 8640051. DOI: 10.1038/s41467-021-27375-5.
Framer A Ther Adv Psychopharmacol. 2021; 11:2045125321991274.
PMID: 33796265 PMC: 7970174. DOI: 10.1177/2045125321991274.
Hellberg S, Russell T, Robinson M Cogn Affect Behav Neurosci. 2018; 19(3):737-758.
PMID: 30357661 PMC: 6482104. DOI: 10.3758/s13415-018-00662-3.